Randomized trial · people
Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeks
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a large placebo-controlled trial, weekly semaglutide improved liver biopsy results in people with MASH and moderate or advanced scarring, with more gut side effects than placebo.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 1197
- Published
- 2025
- Journal
- N Engl J Med
What they tested
Could once-weekly semaglutide improve the liver in people with MASH and moderate or advanced liver scarring?
How the study was done
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial in 1197 patients with biopsy-confirmed MASH (metabolic dysfunction-associated steatohepatitis, a fatty liver disease with inflammation) and fibrosis (scarring) stage 2 or 3. Patients got weekly semaglutide 2.4 mg shots or placebo (a dummy shot) in a 2:1 ratio over a planned 240 weeks, and this planned interim analysis covers the first 800 patients at week 72.

Model. Individual results vary.
What they found
Steatohepatitis cleared up without fibrosis getting worse in 62.9% of the 534 patients on semaglutide and 34.3% of the 266 on placebo, an estimated difference of 28.7 percentage points. Fibrosis improved without steatohepatitis getting worse in 36.8% on semaglutide and 22.4% on placebo. Both happened together in 32.7% and 16.1%, and body weight changed by -10.5% with semaglutide and -2.0% with placebo. Bodily pain scores did not differ significantly between groups, and gut-related side effects were more common with semaglutide.
What it doesn’t show
These are 72-week interim results from the first 800 patients in a trial still running toward 240 weeks, so longer-term outcomes are not yet known. The trial was funded by Novo Nordisk.
The paper
Sanyal et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025.
The compound
More studies on Semaglutide
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetesRandomized trial · people · 2025
- Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4Randomized trial · people · 2025
- Semaglutide 7.2 mg: 18.7% weight loss at 72 weeks in STEP UPRandomized trial · people · 2025
- Every study on Semaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.